Saliva test aims to detect HPV throat cancer

Share This Post

A Queensland University of Technology (QUT) researcher is developing a simple saliva test to detect human papillomavirus (HPV) in laryngeal cancer. This is an extension of cooperation with Johnson & Johnson, Jensen Vaccine Prevention, and Jensen Sidip Ltd.

Professor Chamindie Punyadeera from the QUT Institute of Health and Biomedical Innovation (IHBI) said that with the development of new therapeutic vaccines, it is important to identify those in the general population who should receive vaccine treatment. In the early stages of HPV-induced laryngeal cancer, identifying high-risk groups will help prevent cancer from worsening.

Highly sensitive diagnosis based on saliva provides a possibility to detect human HPV infection in a low-cost, non-invasive way.

The new therapeutic vaccine is expected to have an immediate impact on the prevalence of HPV-related malignancies.

Professor Punyadeera said HPV throat cancer has proven to be more difficult to identify than cancers caused by smoking.

She said the goal of the new technology is to identify people who are at risk for laryngeal cancer and intercept them before they develop symptoms such as sore throat, difficulty swallowing, or a lump in the neck or throat.

This way, diagnosis and early treatment can begin before invasive treatment is required.

Punyadeera’s research has developed a diagnostic saliva flush test that can help general practitioners, oncologists, and dentists to detect early-stage throat cancer. We hope that a simple, non-invasive saliva sample will be sent to the laboratory or field test to determine whether the patient needs further examination.

Professor Punyadeera said: Ultimately, we hope to develop a test that allows patients to perform home tests and monitoring.

For details on head & neck cancer treatment and second opinion, do call us at +91 91741 52285 or write to

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy